Rocbrutinib
- Generic Name
- Rocbrutinib
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic LymphomaCLL/SLLChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Zulfa Omer
- Target Recruit Count
- 34
- Registration Number
- NCT06978088
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Target Recruit Count
- 112
- Registration Number
- NCT06251180
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Mass Balance Study of LP-168 in Healthy Subjects
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Target Recruit Count
- 6
- Registration Number
- NCT06126861
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Target Recruit Count
- 62
- Registration Number
- NCT05716087
- Locations
- 🇨🇳
Beijing Friendship hospital, Beijing, China
🇨🇳Anhui provincial cancer hospital, Hefei, Anhui, China
🇨🇳The first affiliated hospital of Anhui medical university, Hefei, Anhui, China
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1
Recruiting
- Conditions
- Hairy Cell LeukemiaWaldenstrom MacroglobulinemiaCLL/SLLMantle Cell LymphomaMarginal Zone LymphomaFollicular LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04775745
- Locations
- 🇺🇸
Duke Univerisity, Durham, North Carolina, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath